+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dynavax Technologies Corporation - logo

Dynavax is a clinical-stage biopharmaceutical company with multiple product candidates in development for the treatment of autoimmune and inflammatory diseases, and the treatment of cancer. The company’s lead product candidates include HEPLISAV-B, an investigational adult hepatitis B vaccine; and AZD1419, which is in Phase II clinical trial for the treatment of asthma. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.

From
From
Cancer Vaccines Global Market Report 2024 - Product Thumbnail Image

Cancer Vaccines Global Market Report 2024

  • Report
  • February 2024
  • 250 Pages
  • Global
From
From
From
From
Collaboration Deals in Pharmaceuticals 2019-2024 - Product Thumbnail Image

Collaboration Deals in Pharmaceuticals 2019-2024

  • Report
  • March 2024
  • 1000 Pages
  • Global
From
From
Anthrax - Pipeline Review, H2 2020 - Product Thumbnail Image

Anthrax - Pipeline Review, H2 2020

  • Drug Pipelines
  • July 2020
  • 126 Pages
  • Global
From
From
From
B-Cell Chronic Lymphocytic Leukemia - Pipeline Insight, 2024 - Product Thumbnail Image

B-Cell Chronic Lymphocytic Leukemia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2019 - Product Thumbnail Image

Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 84 Pages
  • Global
From
From
From
Liver Fibrosis Market Report and Forecast 2024-2032 - Product Thumbnail Image

Liver Fibrosis Market Report and Forecast 2024-2032

  • Report
  • February 2024
  • 180 Pages
  • Global
From
Loading Indicator